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Hyperekplexia, which is also known as startle disease, is 
a very rare paroxysmal neurogenetic disorder. It is also one 
cause of Sudden Infant Death Syndrome (SIDS). Hypertoni-
city and exaggerated startle reflex caused by visual, auditory 
or tactile stimuli in the newborn are the key clinical findings 
of hyperekplexia [1]. Molecular genetic studies have revealed 
that mutations in the genes coding postsynaptic proteins and 
the glycine receptors which control postsynaptic inhibition 
in the spinal cord and other regions of the central nervous 
system are responsible for this disease [2, 3]. The disease has 
been primarily and most frequently associated with a muta-
tion in the gene that codes the alpha-1 subunit of the glycine 
receptor which is located on 5q33.1. It has been associated 
with heterozygous, homozygous or compound heterozygous 
mutations in the GLRA1 gene which can exhibit autosomal 
dominant or recessive traits, and has been subgrouped as 
hyperekplexia-1 in the literature [4]. 
We here report the case of a two-month-old girl with 
a prediagnosis of hyperekplexia due to clinical and electrop-
hysiological features, who was subsequently diagnosed with 
hyperekplexia as a result of target gene analysis which revealed 
a deletion in the GLRA1 gene. The patient, who had been 
on antiepileptic medicine since she was two weeks old, was 
admitted due to startling and jerking caused by unexpected 
sounds and touching which occurred both when awake and 
when asleep, and were first seen in the first postnatal week. 
She was born via spontaneous vaginal delivery at the end of 
a non-problematic pregnancy to parents who were third de-
gree relatives. Family history was negative for hyperekplexia 
and SIDS. She had a high frequency, low amplitude tremor 
accompanied by tonic contractions of the upper and lower 
extremities which was first noticed when she was one week 
old, and was also observed during neurological examination. 
Her parents stated that these tremors happened 20–25 times 
a day following auditory and tactile stimuli, and were often 
accompanied by perioral cyanosis. 
She had been seen by a paediatric neurologist and was first 
given phenobarbital (6 mg/kg/day divided into two doses) 
but levetiracetam (30 mg/kg/day divided into two doses) was 
added when she did not respond to that treatment. Video 
electroencephalography (V-EEG) revealed a specific recording 
simultaneous to tonic contractions throughout the body which 
were caused by a tactile stimulus. 
The recording had rhythmic, monomorphic spikes in the 
beta frequency which abruptly initiated from the posterior 
parts of bilateral hemispheres and were constant and did 
not change or evolve. These waves were abruptly terminated 
simultaneous to the termination of tonic seizures and showed 
generalised background slowing, which lasted for 2–3 seconds 
in the EEG (Fig. 1). Cranial magnetic resonance imaging 
(MRI) and metabolic panel (liver and kidney function tests, 
tandem mass, organic acids, pyruvate and lactate) were within 
normal limits.
Therefore the patient aged two months was diagnosed 
with hyperekplexia based on the occurrence of all episodes 
with stimulus and video electroencephalographic features. 
All antiepileptic treatment was stopped, and clonazepam tre-
atment was initiated. Clonazepam was given in three divided 
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doses starting with 0.05 mg/kg/day and increased to the target 
dose of 0.15 mg/kg/day. A dramatic response to clonazepam 
treatment was observed.
A genetic study targeted at the GLRA1 gene for the pre-
diagnosis of hyperekplexia was carried out, and a homozygous 
deletion between exons 1–7 was found. The GLRA-1 gene has 
nine exons, and the homozygous deletion in our patient was 
consistent with a complete loss of gene function. The diagnosis 
was confirmed by a molecular genetic study which was per-
formed in the third month of life, and the family was offered 
genetic counselling regarding future pregnancies. 
In the last follow up, which was performed when the 
patient was under clonazepam treatment and was six months 
old, the tonic spasms had completely disappeared although 
minor jerks following tactile stimuli had not. There were no 
side effects of the treatment and the patient’s development 
was normal, despite the cases reported in the literature with 
delayed motor development [5]. Also, there is no history of 
apnoea attacks. 
Hyperekplexia is a rare non-epileptic phenomenon which 
clinicians often mistake for epilepsy in their daily practice. 
Hyperekplexia is known to be caused by a variety of genes 
encoding both pre- and postsynaptic proteins. The symptoms 
displayed, as well as the forms of heritance, vary according to 
which gene is affected. 
In terms of the type of mutation in the GLRA1 gene, it 
should also be noted that deletion is extremely rare in the 
reported cases. It is very important to recognise the spe-
cific clinical features, to evaluate electroencephalographic 
patterns in conjunction with clinical findings, and to offer 
counselling to the families about responses to therapy and 
the genetic traits of this disease. As a result, hyperekplexia 
is a neurogenetic disorder which must be borne in mind 
by general practitioners, paediatricians, and paediatric 
neurologists.  
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Figure 1. EEG findings of the patient during tonic contractions
